Akcea Expects Convenience Edge For Tegsedi, Despite Monitoring Requirements

08 Oct 2018

Approved two months after Alnylam’s Onpattro, Tegsedi is priced almost identically in the same hATTR indication. Ionis affiliate Akcea hopes weekly subcutaneous administration will provide convenience benefit compared to I.V. Onpattro.

Sarah Boyce of Akcea — Akcea President Sarah Boyce

Akcea Therapeutics Inc. has reached the market with Tegsedi, its RNA-interference (RNAi) therapy for hereditary transthyretin-mediated amyloidosis (hATTR) related polyneuropathy, just a couple months after Alnylam Pharmaceuticals Inc. received US FDA approval for its similar drug Onpattro for the same indication. The similarities will extend to pricing, as Akcea announced it will price Tegsedi roughly on par with Onpattro.

Tegsedi (inotersen) cleared the US FDA Oct. 5 for hATTR polyneuropathy, after Alnylam’s Onpattro (patisiran) got the okay on Aug. 10 as the first drug therapy for the rare disease

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

16 May 2025

• By Vibha Ravi

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.